flsh56
3週前
Ha yourself, lol...
Lets see how the institutional ownership percentage changes on the next report. It currently stands at just under 17%
But keep up the great "wow" cheerleading and watching every second the stock trades, lol, lol, lol
What are you going to be like when we get to $20, $30, ha ha...
I'm saving my "wow" for if the Knicks sweep the Cavs, and of course if/when, as we all believe, for stellar trial results, and for if the trial fills by the end of June and for if my dream scenario plays out... as for intraday trading, I'll leave that "wow" one for you, lol
Enjoy the holiday weekend!
abew4me
3週前
Quote: "It's not that unusual of a buy (250,000) when there are 7,895,000 newly issued shares hitting the market."
LOL...that's one of the most ridiculous statements I have ever read!
Just because a company issues 7.9 million new shares onto the market, doesn't mean that institutions will start buying large chunks of 250,000 shares on the open market.
Canaccord agreed to buy those shares directly from the company...and will now resell them in accordance with the agreement with Annovis. (Click the link below for full details)
*****************************************************************************************************
UNDERWRITING
Subject to the terms and conditions set forth in the underwriting agreement, dated May 20, 2026, between the Company and Canaccord Genuity LLC (the “underwriter”), the Company has agreed to sell to the underwriter, and the underwriter has agreed to purchase from the Company, the number of securities set forth opposite its name below.
http://archive.fast-edgar.com/20260520/ABB2I22C8Z22GJZA22T92ZZZHMNR72R2Z282/
abew4me
4週前
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of issuance.
All of the shares of common stock and the accompanying warrants are being offered by Annovis. The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering.
Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $15.0 million, excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.
Canaccord Genuity is acting as the sole bookrunner in the offering.
Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in clinical studies for Alzheimer’s disease (AD) and Parkinson’s Disease (PD) and for working capital and general corporate purposes.
The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
abew4me
4週前
It was a P3. Their drug was effective for all of the participants...but the placebo group also had an improvement with their cognitive tests. They were puzzled by this anomaly and found that many of the participants in the P3 study were not suffering from cognitive decline but were admitted to the trial anyway. (See below)
Beyond Perfection: How Mistakes Shape Path to Approval
https://events.reutersevents.com/pharma/article/beyond-perfection-how-mistakes-shape-path-to-approval
After you're finished reading that article, you can read the company's release of the P3 results below. (And btw, after they released the results of the P3 data, there was a slew of insider buying all the way up to $4+ per share)
http://archive.fast-edgar.com/20251208/ALBZM22D8C22H9ZZ2R2B2ZZZKUONZ2Q2ZB72/
30,000 shares at $4.34
15,000 shares at $4.24
****************************************************************************************************************
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
- Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response
- New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap treatment
- Findings support buntanetap's potential to address cognitive decline in Parkinson's disease, show disease-modifying efficacy, and inform future clinical development
MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new data demonstrating the impact of amyloid co-pathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap in this population.
In the Company’s Phase 3 study in early PD (NCT05357989), buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. Further analysis revealed that approximately 25% of them exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which was counteracted and reversed by buntanetap.
These findings reinforce a central principle long championed by Annovis: neurodegenerative diseases rarely occur in isolation. Instead, multiple neurotoxic proteins—those implicated in both Alzheimer’s and Parkinson’s—drive cognitive and functional decline. Addressing this complexity requires therapies capable of targeting several toxic proteins simultaneously, which is precisely what buntanetap does.
As anticipated, buntanetap treatment led to significant cognitive improvement in Parkinson’s patients with amyloid co-pathology. This response was further supported by measurable reductions in pTau217, total tau, and brain-derived (BD) tau – well-established biomarkers of neurodegeneration used in AD. Together, these findings indicate that buntanetap is actively modulating the underlying drivers of cognitive deterioration, ultimately broadening the population of patients who may benefit from treatment.
"What we see is that Parkinson's patients who experience cognitive decline also have Alzheimer's pathology, and our drug helps them," commented Cheng Fang, Senior VP, Research & Development. "These data are the first of its kind—no one has previously looked into treatment effects in Parkinson's patients with amyloid co-pathology. The findings integrate seamlessly with our growing body of clinical evidence, distinguishing buntanetap as a promising therapeutic candidate for cognitive improvement across multiple neurodegenerative diseases."
The full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, December 1-4, 2025. Additional details regarding the presentation will be announced closer to the conference date via a separate news release.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
shortridge3w
4週前
Predicting the exact market capitalization for a clinical-stage biotechnology company like Annovis Bio (\bm{ANVS}) upon a regulatory approval is speculative, as the market's reaction depends on several dynamic variables.
Currently, Annovis Bio has a micro-cap valuation fluctuating between $65 million and $75 million, with approximately 28.5 million to 34 million shares outstanding (following recent dilutive capital raises, such as their $10 million offering in April 2026).
If buntanetap secures FDA approval strictly for symptomatic effects (e.g., improving cognitive function in Alzheimer's or motor function in Parkinson's without a proven disease-modifying, neuroprotective label), the potential market capitalization can be evaluated through a few key lenses:
1. The Market Pricing of Symptomatic vs. Disease-Modifying Labels
Symptomatic treatments generally command lower valuation multiples than true disease-modifying therapies (like anti-amyloid antibodies) because they do not halt the underlying pathology. However, given the massive size of the Alzheimer's and Parkinson's patient populations, a clean symptomatic drug with a favorable safety profile can still achieve blockbuster or near-blockbuster status.
2. Standard Biotech Valuation Multiples
If buntanetap is approved, analysts will model its peak sales based on market penetration, pricing, and insurance coverage.
• Conservative Peak Sales: If buntanetap achieves modest adoption, generating an estimated $250 million to $500 million in peak annual revenue.
• Valuation Multiples: Approved, commercial-stage biotechs with growing revenues typically trade at a price-to-sales (\bm{P/S}) multiple of 3x to 5x peak sales.
• Implied Market Cap: This standard framework implies a post-approval valuation range of $750 million to $2.5 billion.
3. Comparing the Valuation "Infection Point"
For a micro-cap company (~$70M) to transition to an approved asset owner, the valuation multiplier is often dramatic. A leap to a $1 billion to $2 billion market cap represents roughly a 15x to 30x return from current levels. This is a common trajectory for small biotechs successfully crossing the finish line into a multi-billion dollar market, though it is often accompanied by further dilutive financing to build out a commercial sales force or manufacturing infrastructure.
Ultimately, while an approval for symptomatic benefits is a massive milestone that could easily lift Annovis into the $1B+ club, the exact cap will depend on the final FDA label, the drug's safety data compared to existing treatments, and whether they partner with a major pharmaceutical firm for commercial distribution.
flsh56
4週前
Full enrollment as per yesterdays company guidance will be summertime....
Whether that is the end of June, sometime in early July, July, or even early August, enrollment is going very very well and the trial will fill very very soon.
Once again, your enthusiastic prediction (exclamation point) could be interpreted as cheerleading unless you have a better window into the trial than the company.
Brava if Maria pr's this in early summer. As investors, we should applaud when mgmt over delivers. On this note, ok, I will applaud your "guess", this one time.
abew4me
1月前
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
- Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026
- PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026
- New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028
Malvern, PA, May 15, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the first quarter ended March 31, 2026.
"We saw strong momentum across both our AD and PD programs in the first quarter," said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap."
Clinical highlights
Alzheimer’s disease – pivotal Phase 3 trial (NCT06709014)
- Enrollment: 85% of patients enrolled.
- Screening: On May 15, 2026, Annovis closed enrollment to new participants after reaching a sufficient number of patients in screening to meet the trial's enrollment goal.
- Safety: Annovis received a positive recommendation from the Data and Safety Monitoring Board (DSMB) regarding the drug’s safety at 6 months, supporting seamless continuation of the study.
- Study design: The pivotal Phase 3 AD trial is recruiting early AD patients positive for pTau217 plasma biomarker. The study is designed to evaluate buntanetap's symptomatic effect at 6 months and its potential disease-modifying effect at 18 months.
Parkinson’s disease – OLE study (NCT07284784)
- Enrollment: 40% of patients enrolled.
- Skin biomarker: The PD OLE study is implementing a biomarker test measuring levels of phosphorylated alpha-synuclein and nerve cell fiber density via skin biopsy.
- Digital biomarker: Annovis entered into a partnership with NeuroRPM to integrate an AI-powered digital biomarker, enabling continuous, real-world assessment of motor functions in response to buntanetap.
- Study design: The PD OLE study is designed to evaluate buntanetap's safety and long-term efficacy over the period of 36 months in participants from prior Annovis’ trials as well as in new patients who had deep brain stimulation (DBS) surgery.
Corporate highlights
Publications
- Annovis published a byline article in The Scientist, tracing the 170-year scientific history of buntanetap, from the origins of its predecessor compound to its mechanism of action and key events that shaped the drug’s clinical development.
- Annovis announced a peer-reviewed publication of the Phase 2/3 AD clinical trial results in Nature NPJ Dementia, available open access, demonstrating a dose-dependent cognitive improvement and biomarker reductions in patients treated with buntanetap.
Presentations
- Cheng Fang, Ph.D., SVP, R&D, presented two posters at the AD/PD2026 conference, highlighting clinical data which support buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings as well as an update on the ongoing pivotal Phase 3 AD trial.
- Maria Maccecchini, Ph.D., President and CEO, presented at Fierce Biotech Week 2026 in Boston, delivering a talk titled "The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept," making the scientific case for targeting multiple neurotoxic proteins in AD and presenting buntanetap's clinical evidence of cognitive and biomarker improvements.
Patents
Annovis secured a U.S. patent, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds.
Upcoming milestones
- Phase 3 AD study: Annovis expects to reach full enrollment in summer 2026. The symptomatic data readout is anticipated approximately 6 months after the last patient is dosed. The disease-modifying data readout is anticipated 18 months after the last patient is dosed.
- PD OLE study: Annovis expects to complete enrollment for the PD OLE study in the fourth quarter of 2026.
- NDA pathway: Based on the Phase 3 AD study outcomes, Annovis plans to engage with the FDA regarding a regulatory NDA submission for buntanetap as a symptomatic treatment for AD in early 2027 and as a disease-modifying treatment in early 2028.
Financial results
Annovis’ cash and cash equivalents totaled $14.2 million as of March 31, 2026, compared to $19.5 million as of December 31, 2025. This excludes gross proceeds from its recent $10.0 million registered direct offering on April 10, 2026. Annovis had 28.5 million shares of common stock outstanding as of March 31, 2026.
Research and development expenses for the three months ended March 31, 2026, were $16.7 million compared to $5.0 million for the three months ended March 31, 2025.
General and administrative expenses for the three months ended March 31, 2026, were $1.3 million compared to $1.3 million for the three months ended March 31, 2025.
Annovis reported a $0.63 basic and diluted net loss per common share for the three months ended March 31, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended March 31, 2025.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
abew4me
1月前
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026.
- Title: "The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept" [This is a MUST WATCH]
- Presenter: Maria Maccecchini, Ph.D., President and CEO
- Date: Wednesday, May 13, 2026
- Time: 1:40 PM - 2:05 PM
- Location: Picasso 4&5
The presentation will trace the scientific foundation for understanding AD as a disease driven by multiple neurotoxic aggregating proteins and examine the historical gap between that evidence and the field's reliance on a single-protein approach. Dr. Maccecchini will make the case supporting the importance of the full spectrum of neurotoxic proteins – including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression, which are not only backed by decades of scientific data but also represent a promising path forward for the AD drug development.
"Alzheimer's disease has never been a one-protein problem, and overreliance on amyloid as the sole driver of the disease has come at a cost, hindering progress for alternative therapeutic candidates," said Maria Maccecchini, Ph.D., President and CEO. "Annovis’ program is built exactly on the premise that simultaneous reduction of the overexpression of several aggregating proteins interrupts the toxic cascade and improves the health of nerve cells. Our lead drug buntanetap, a translational inhibitor of these proteins, has already shown meaningful clinical benefits supported by encouraging biomarker data, and is now in a pivotal Phase 3 clinical trial."
The presentation will be followed by a Q&A discussion and is open to all participants.
Fierce Biotech Week 2026 brings together leaders across R&D, clinical development, business development, and communications to confront the industry's most pressing challenges, from capital strategy and pipeline advancement to partnership formation and commercialization. With more than 100 biotech CEOs and founders, over 500 companies, and 15 top global pharmaceutical organizations represented, the event is built for the leaders driving consequential decisions.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Bourbon_on_my_cornflakes
4週前
メールアドレスで登録
